Exscientia Plc (EXAI) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Exscientia plc has entered into a definitive agreement for acquisition by Recursion Pharmaceuticals, with the transaction aimed at combining their complementary portfolios and technology platforms to accelerate drug discovery and development. Exscientia shareholders are urged to vote on the proposed scheme of arrangement, which will involve exchanging each Exscientia share for 0.7729 shares of Recursion Class A Common Stock. The success of the acquisition hinges on the approval of both Recursion stockholders and Exscientia shareholders, with a special meeting scheduled for November 12, 2024.
For further insights into EXAI stock, check out TipRanks’ Stock Analysis page.